drugset
drugset / Trial / NCT01573663

A Drug-Drug Interaction Study of Ambroxol and Levodropropizine

NCT01573663 ↗

Phase 1 Completed 21 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the drug-durg interaction between ambroxol and levodropropizine.

Timeline

Start
2012-02
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambroxol Small molecule 30 mg Oral
Subject Levodropropizine Small molecule 60 mg Oral

Indications

No indication recorded.